Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors

<p>Glioblastoma patient characteristics (DFCI)</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Joseph Toker (15399882) (author)
مؤلفون آخرون:	J. Bryan Iorgulescu (15030477) (author), Alexander L. Ling (15399885) (author), Genaro R. Villa (15399888) (author), Josephina A.M.A. Gadet (15399891) (author), Laxmi Parida (15112564) (author), Gad Getz (14945542) (author), Catherine J. Wu (14944480) (author), David A. Reardon (15043854) (author), E. Antonio Chiocca (15399894) (author), Marco Mineo (15399897) (author)
منشور في:	2025
الموضوعات:	Cancer Cancer Detection and Diagnosis Immuno-oncology Biomarkers CNS Cancers Gliomas, Glioblastomas Immunotherapy Checkpoint blockade Skin Cancers Melanoma
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
حسب: Joseph Toker (15399882)
منشور في: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
حسب: Joseph Toker (15399882)
منشور في: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
حسب: Joseph Toker (15399882)
منشور في: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
حسب: Joseph Toker (15399882)
منشور في: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
حسب: Joseph Toker (15399882)
منشور في: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
حسب: Joseph Toker (15399882)
منشور في: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
حسب: Isha Mondal (16721699)
منشور في: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
حسب: Francesca Orzan (15055579)
منشور في: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
حسب: Francesca Orzan (15055579)
منشور في: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
حسب: Francesca Orzan (15055579)
منشور في: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
حسب: Michael Kilian (16697663)
منشور في: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
حسب: Michael Kilian (16697663)
منشور في: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
حسب: Michael Kilian (16697663)
منشور في: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
حسب: Sied Kebir (15048732)
منشور في: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
حسب: Sied Kebir (15048732)
منشور في: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
حسب: Sied Kebir (15048732)
منشور في: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
حسب: Sied Kebir (15048732)
منشور في: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
حسب: Sied Kebir (15048732)
منشور في: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
حسب: Defne Bayik (14961098)
منشور في: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
حسب: Qingsheng Xu (17078830)
منشور في: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
حسب: Qingsheng Xu (17078830)
منشور في: (2025)

Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
حسب: Reza Mirzaei (15306062)
منشور في: (2025)

Supplementary Table S1 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
حسب: Reza Mirzaei (15306062)
منشور في: (2025)

Supplementary Table S2 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
حسب: Reza Mirzaei (15306062)
منشور في: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
حسب: Bachchu Lal (17141949)
منشور في: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
حسب: William Kelly (15439117)
منشور في: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
حسب: William Kelly (15439117)
منشور في: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
حسب: Tobias Kessler (17079209)
منشور في: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
حسب: Tobias Kessler (17079209)
منشور في: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
حسب: Tobias Kessler (17079209)
منشور في: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
حسب: Tobias Kessler (17079209)
منشور في: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
حسب: Tobias Kessler (17079209)
منشور في: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
حسب: Tobias Kessler (17079209)
منشور في: (2025)

Cannot write session to /tmp/vufind_sessions/sess_g3fkt43j2jfj6vlhbae3qro7v2